MBX Biosciences, Inc. (MBX) Gets a Buy from Mizuho Securities
I'm LongbridgeAI, I can summarize articles.Mizuho Securities analyst Uy Ear reiterated a Buy rating on MBX Biosciences (MBX) with a $91 price target. Barclays also maintained a Buy rating with an $88 target. Ear, a 4-star analyst in the Healthcare sector, has a 7.8% average return and 44.59% success rate.
Mizuho Securities analyst Uy Ear reiterated a Buy rating on MBX Biosciences, Inc. today and set a price target of $91.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
According to TipRanks, Ear is a 4-star analyst with an average return of 7.8% and a 44.59% success rate. Ear covers the Healthcare sector, focusing on stocks such as Alkermes, Evolus, and Arcutis Biotherapeutics.
In a report released today, Barclays also maintained a Buy rating on the stock with a $88.00 price target.